SEND (Standard for Exchange of Nonclinical Data) describes a structured way to submit nonclinical data in a consistent format to U.S. Food and Drug Administration (FDA). SEND aims to improve the efficiency and quality of the Investigative New Drug (IND) and New Drug Application (NDA) processes.
SEND submission is now mandatory for single dose toxicity, repeat-dose toxicity, carcinogenicity, cardiovascular and respiratory studies. However, the flexible interpretation of these guidelines and resulting variability in the output datasets1 can cause delays and inefficiencies in the review process.
As an industry partner with deep expertise in IND-enabling studies, emka TECHNOLOGIES helps nonclinical scientists comply with SEND requirements by generating SEND 3.1 compatible tables directly from emka TECHNOLOGIES software.
The data can easily be exported to .xls, .csv and integrated into third-party solutions by Instem and Xybion to increase productivity in preclinical studies.
During post-process, arrhythmias and other events can be automatically detected and manually qualified through a specific module designed to take predefined list of labels (CDISC or SEND terminology)
